Merck (MRK) Announces Presentation of Data from Three KEYTRUDA Studies; Strong Anti-Tumor Activity Observed
Tweet Send to a Friend
Merck (NYSE: MRK) announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in combination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
